Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

No phase data available

Loading network data...

Showing 5 of 5 trials

Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease

Role: lead

Prognosis Value of Transient Elastography and Non-invasive Markers of Fibrosis in Patients With Chronic Liver Disease

Role: lead

Prospective Evaluation of FibroScan in Patients Treated With Methotrexate

Role: lead

Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir

Role: lead

Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study

Role: lead

All 5 trials loaded